Evotec’s kidney ‘chip’ to test drugs and speed-up trials

By Flora Southey

- Last updated on GMT


Related tags Kidney Clinical trial Stem cell

Evotec is collaborating with academic institutions to develop a device to test drug candidates in the kidney, which it says could improve and accelerate clinical trials.

The contract research organisation (CRO) described the Nexplex technology as a ‘nephron-on-a-chip’, which reflects both the filtration area as well as the resorption area of a human kidney.

“The functional nephrons will be based on fully characterised human cell lines and induced pluripotent stem cell (iPSC)-derived human kidney cells,” ​said spokesperson Gabriele Hansen.

Under the agreement, UK-based University of Bristol and the University of Cambridge will provide human kidney cell lines and develop the glomerular – a network of capillaries in the kidney – part of the chip respectively.

Milan, Italy-based Mario Negri Institute will provide human iPSC lines, and Evotec, who is funding the programme, will contribute its iPSC and kidney disease platforms. 

Hansen told us Nexplex will accelerate and improve Evotec’s preclinical trial services, describing it as a ‘step forward to the next generation kidney platform.’

The firm did not disclose financial details of the deal, nor the cost of the technology.

“Since this will be a very unique device that will significantly improve and accelerate the drug discovery in the field of kidney diseases, the overall value will certainly outnumber development costs,” ​said Hansen.

Evotec continues to expand its clinical trial capabilities, announcing​ it had completed the acquisition of preclinical CRO Cyprotex in December last year.

In August, the firm announced​ it had completed the acquisition of Aptuit. 

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Follow us


View more